<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230838</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-034</org_study_id>
    <secondary_id>2016-004153-32</secondary_id>
    <nct_id>NCT03230838</nct_id>
  </id_info>
  <brief_title>MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)</brief_title>
  <official_title>A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam)&#xD;
      compared with that of meropenem in pediatric participants with cUTI, including&#xD;
      pyelonephritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Actual">December 3, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to Day 49</time_frame>
    <description>The number of participants with one or more AEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study therapy due to AE</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>The number of participants who discontinued study intervention due to an AE will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a clinical response of cure</measure>
    <time_frame>Up to Test of Cure Visit (up to 23 days)</time_frame>
    <description>The percentage of participants who have a clinical response of cure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with microbiological eradication of all baseline pathogens</measure>
    <time_frame>Up to Test of Cure Visit (up to 23 days)</time_frame>
    <description>The percentage of participants who have microbiological eradication or presumed eradication of all baseline pathogens will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose) administered intravenously (IV) every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane</intervention_name>
    <description>Ceftolozane 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 7 to 14 days</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days. At the investigator's discretion, some participants may receive meropenem up to 30 mg/kg.</description>
    <arm_group_label>Meropenem</arm_group_label>
    <other_name>MERREM®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a legally acceptable representative who provides documented informed consent /&#xD;
             assent for the trial.&#xD;
&#xD;
          -  Ages from birth (defined as &gt;32 weeks gestational age and ≥7 days postnatal) to &lt;18&#xD;
             years of age.&#xD;
&#xD;
          -  Requires IV antibacterial therapy for the treatment of cUTI.&#xD;
&#xD;
          -  Have a pretreatment baseline urine culture specimen obtained within 48 hours before&#xD;
             the start of administration of the first dose of study treatment and preferably prior&#xD;
             to administration of any potentially therapeutic antibiotics.&#xD;
&#xD;
          -  Has pyuria.&#xD;
&#xD;
          -  Has clinical signs and/or symptoms of cUTI at the Screening Visit.&#xD;
&#xD;
          -  Is not of reproductive potential; but if of reproductive potential agrees to avoid&#xD;
             becoming pregnant or impregnating a partner during screening, while receiving study&#xD;
             treatment and for at least 30 days after the last dose of study treatment.&#xD;
&#xD;
          -  Female of reproductive potential is not pregnant, and not planning to become pregnant&#xD;
             within 30 days of the last day of treatment administration; and is nonlactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 30 days prior to the first dose of&#xD;
             study treatment in this current trial.&#xD;
&#xD;
          -  Has previously participated in any trial of ceftolozane or ceftolozane/tazobactam or&#xD;
             has enrolled previously in the current trial and been discontinued.&#xD;
&#xD;
          -  Has a history of any moderate or severe hypersensitivity (eg, anaphylaxis), allergic&#xD;
             reaction, or other contraindication to any of the following: β-lactam antibiotics (eg,&#xD;
             penicillins, cephalosporins, and carbapenems), β-lactamase inhibitors (eg, tazobactam,&#xD;
             sulbactam, clavulanic acid, avibactam), or metronidazole.&#xD;
&#xD;
          -  Has a history of a cUTI within the past 1 year prior to randomization known to be&#xD;
             caused by a pathogen resistant to either IV study treatment.&#xD;
&#xD;
          -  Has a concomitant infection at the time of randomization that requires nonstudy&#xD;
             systemic antibacterial therapy in addition to IV study treatment or oral step -down&#xD;
             therapy.&#xD;
&#xD;
          -  Has received potentially therapeutic antibacterial therapy for a duration more than 24&#xD;
             hours during the 48 hours preceding the first dose of study treatment.&#xD;
&#xD;
          -  Has any of the following: a) intractable UTI or pyelonephritis infection at baseline&#xD;
             that the Investigator anticipates would require more than 14 days of study treatment;&#xD;
             b) confirmed fungal urinary tract infection at time of randomization; c) permanent&#xD;
             indwelling bladder catheter or instrumentation including nephrostomy; d) current&#xD;
             urinary catheter that is not scheduled to be removed before the end of all study&#xD;
             treatment; e) complete, permanent obstruction of the urinary tract; f) suspected or&#xD;
             confirmed perinephric or intrarenal abscess; g) documented ileal loop reflux; h)&#xD;
             suspected or confirmed prostatitis, urethritis, or epididymitis; i) trauma to&#xD;
             pelvis/urinary tract.&#xD;
&#xD;
          -  Has moderate or severe impairment of renal function.&#xD;
&#xD;
          -  Has a seizure disorder or is anticipated to be treated with divalproex sodium or&#xD;
             valproic acid during the course of study treatment.&#xD;
&#xD;
          -  Is receiving, or is expected to receive, any prohibited medications.&#xD;
&#xD;
          -  Has any rapidly progressing disease or immediately life-threatening illness, including&#xD;
             acute hepatic failure, respiratory failure, or septic shock.&#xD;
&#xD;
          -  Has an immunocompromising condition.&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent.&#xD;
&#xD;
          -  Is planning to receive suppressive/prophylactic antibiotics with gram-negative&#xD;
             activity after completion of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 2509)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 2502)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 2505)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 2519)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Hospital ( Site 2512)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 2508)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 2510)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health ( Site 2520)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College Of Medicine ( Site 2515)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pan and Aglaia Kyriakou Children s Hospital ( Site 0780)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens - Aghia Sophia Childrens Hospital ( Site 0730)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens University Hospital ATTIKON ( Site 0790)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa ( Site 0740)</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki ( Site 0700)</name>
      <address>
        <city>Thessaloniki</city>
        <state>Thessaloníki</state>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE AOK Klinikai Kozpont ( Site 0809)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0804)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SzSzBMK es Egyetemi Oktatokorhaz Josa Andras Oktatokorhaz ( Site 0808)</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem ( Site 0810)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0801)</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0803)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 1202)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 1204)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 1201)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 1203)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 1606)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 1600)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. Rydgiera ( Site 1607)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki ( Site 1602)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniw. Szpital Dzieciecy w Krakowie ( Site 1609)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1608)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Maria Sklodowska Curie ( Site 1707)</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>041451</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spit. Cl. de Urg. Copii Cluj Napoca ( Site 1708)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400177</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Brasov ( Site 1703)</name>
      <address>
        <city>Brasov</city>
        <zip>500063</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof. Dr. Matei Bals ( Site 1706)</name>
      <address>
        <city>Bucuresti</city>
        <zip>021106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Pediatric Clinical Hospital ( Site 1808)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119571</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 1811)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 1800)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital ( Site 1805)</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Skiy Kray</state>
        <zip>355029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molotlegi Street ( Site 1903)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inkosi Albert Luthuli Central Hospital ( Site 1902)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital ( Site 1900)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 2200)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2201)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Unv. Tip Fakultesi ( Site 2202)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 2203)</name>
      <address>
        <city>Istanbul</city>
        <zip>34453</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 2402)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Kryvorizka city clinical hospital 8 ( Site 2408)</name>
      <address>
        <city>Kryvyy Rig</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50082</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital ( Site 2411)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 2410)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Children Hospital 16 ( Site 2414)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Children Specialised Hospital OHMADYT MOH Ukraine ( Site 2409)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Children s Clinical Hospital of Poltava City Council ( Site 2404)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>November 3, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

